(Q51231723)

English

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

scientific article published on 4 April 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. (English)

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

author name string

Aaron N Nguyen

1

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Elizabeth G Stebbins

2

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Margaret Henson

3

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Gilbert O'Young

4

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Sun J Choi

5

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Diana Quon

6

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Debby Damm

7

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Mamatha Reddy

8

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Jing Y Ma

9

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Edwin Haghnazari

10

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Ann M Kapoun

11

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Satyanarayana Medicherla

12

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Andy Protter

13

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

George F Schreiner

14

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Noriyoshi Kurihara

15

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Judy Anderson

16

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

G David Roodman

17

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Tony A Navas

18

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Linda S Higgins

19

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

language of work or name

0 references

publication date

4 April 2006

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Experimental Cell Research

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

312

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

1909-1923

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

10

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Pathogenesis and management of bone lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Drug resistance and drug development in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The tumor microenvironment: focus on myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

New insights into role of microenvironment in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Advances in biology of multiple myeloma: clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The tumor microenvironment as a determinant of drug response and resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Map kinase signaling pathways and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Adhesion mechanisms regulating the migration of monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Regulation of osteoclast function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Bisphosphonate Induced Growth Inhibition of Breast Cancer Cells is Augmented by p38 Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Bone morphogenetic proteins, their antagonists, and the skeleton

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Wnt signaling in osteoblasts and bone diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Multiple myeloma: evolving genetic events and host interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Anti-myeloma activity of pamidronate in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.02.026

7 January 2021

Identifiers

10.1016/J.YEXCR.2006.02.026

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

1 reference

Europe PubMed Central

1 April 2018

http://europepmc.org/abstract/MED/16600214

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51231723&oldid=1370620069"